company background image
2675 logo

Yantai Dongcheng Pharmaceutical GroupLtd SZSE:002675 Stock Report

Last Price

CN¥14.32

Market Cap

CN¥12.2b

7D

-11.3%

1Y

-9.5%

Updated

27 Mar, 2024

Data

Company Financials +

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

SZSE:002675 Stock Report

Market Cap: CN¥12.2b

2675 Stock Overview

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas.

2675 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance4/6
Financial Health6/6
Dividends3/6

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Yantai Dongcheng Pharmaceutical GroupLtd
Historical stock prices
Current Share PriceCN¥14.32
52 Week HighCN¥20.15
52 Week LowCN¥12.05
Beta0.30
1 Month Change-5.79%
3 Month Change-18.22%
1 Year Change-9.48%
3 Year Change-24.87%
5 Year Change17.96%
Change since IPO140.34%

Recent News & Updates

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Mar 15
Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Feb 27
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Recent updates

Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Mar 15
Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?

Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Feb 27
Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark

Shareholder Returns

2675CN BiotechsCN Market
7D-11.3%-4.9%-2.2%
1Y-9.5%-20.7%-14.8%

Return vs Industry: 002675 exceeded the CN Biotechs industry which returned -20.7% over the past year.

Return vs Market: 002675 exceeded the CN Market which returned -14.8% over the past year.

Price Volatility

Is 2675's price volatile compared to industry and market?
2675 volatility
2675 Average Weekly Movement6.7%
Biotechs Industry Average Movement8.0%
Market Average Movement8.1%
10% most volatile stocks in CN Market11.4%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 002675's share price has been volatile over the past 3 months.

Volatility Over Time: 002675's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19982,174Zhi Gang Luohttps://www.dcb-group.com

Yantai Dongcheng Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the manufacture and sale of biochemical APIs, finished dosage forms, nuclide drugs, and healthy products for cardiovascular, antitumor, urology, orthopedics, and other therapeutic areas. It offers heparin, chondroitin sulphate sodium and calcium, and glucosamine series products, as well as collagen, hyaluronic acid, and cytochrome C. The company also provides nadroparin calcium, hydrocortisone sodium succinate, chorionic gonadotrophin, and menotropins for injection, as well as ambroxol hydrochloride dispersible tablets, jinjunling capsule, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind dispelling itch relieving granule. In addition, it offers Technetium [99Tc] Methylene Diphosphonate Injection; Technetium [99mTc] Tc labeled tracers; 2-[18F]FDG that helps to detect the activity of tumor cells; sodium iodide [131I] oral solution; iodine [125I] seed use to treat internal radiation of various malignant tumors; [14C]Urea capsule; and jiabaolin glucosamine chondroitin sulfate capsule.

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Fundamentals Summary

How do Yantai Dongcheng Pharmaceutical GroupLtd's earnings and revenue compare to its market cap?
2675 fundamental statistics
Market capCN¥12.17b
Earnings (TTM)CN¥262.79m
Revenue (TTM)CN¥3.43b

44.9x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2675 income statement (TTM)
RevenueCN¥3.43b
Cost of RevenueCN¥1.92b
Gross ProfitCN¥1.51b
Other ExpensesCN¥1.25b
EarningsCN¥262.79m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 27, 2024

Earnings per share (EPS)0.32
Gross Margin44.06%
Net Profit Margin7.67%
Debt/Equity Ratio14.7%

How did 2675 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

47%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.